Brief: Onxeo H1 Net Profit At 5 Million Euros

Valerio Therapeutics SA

17/09/2020 16:52

Sept 17 (Reuters) - Onxeo SA  C4X.PA :
    * H1 REVENUE 1.1 MILLION EUR
    * TOPLINE RESULTS OF ASIDNA™ DRIIV-1B STUDY IN COMBINATION
WITH
CHEMOTHERAPY ARE EXPECTED IN LATE 2020/EARLY 2021
    * CASH POSITION OF EUR 19.6 MILLION PROVIDES FINANCIAL
VISIBILITY
INTO Q1 2022
    * PATIENT INCLUSION PROCESS HAS STARTED IN PHASE 1B/2
REVOCAN
STUDY EVALUATING EFFECT OF ASIDNA™ ON RESISTANCE TO NIRAPARIB
AND PRELIMINARY RESULTS ARE EXPECTED IN EARLY 2021
    * OPERATING EXPENSES AMOUNTED TO EUR 5.5 MILLION IN H1 2020
    * NET PROFIT OF EUR 5 MILLION FOR FIRST HALF OF 2020,
COMPARED TO
A LOSS OF EUR 8.5 MILLION IN 2019
    * AT JUNE 30, 2020, COMPANY HAD CONSOLIDATED CASH AND CASH
EQUIVALENTS OF 19.6 MILLION EUROS

Source text for Eikon:  ID:nBw5SDhpva 
Further company coverage:  C4X.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))